PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results
04 mai 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
iSpecimen Reports First Quarter 2023 Results
04 mai 2023 07h00 HE
|
iSpecimen Inc
LEXINGTON, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for...
Arcadis Trading Update Q1 2023
04 mai 2023 01h00 HE
|
Arcadis N.V.
ARCADIS TRADING UPDATE Q1 2023 On track to deliver on strategic targets set for 2023 Net revenue of €940 million, with accelerated organic growth of 12.3%1)Operating EBITA of €92 million,...
Millicom (Tigo) continued strong mobile performance in Q1
27 avr. 2023 06h00 HE
|
Millicom International Cellular S.A.
Millicom (Tigo) continued strong mobile performance in Q1 Luxembourg, April 27, 2023 – Millicom is pleased to announce its first quarter 2023 results. Please find below links to the Q1 2023 Earnings...
Eramet : Chiffre d’affaires de 775 M€ au 1er trimestre 2023
27 avr. 2023 01h30 HE
|
Eramet SA
Paris, le 27 avril 2023, 7h30 COMMUNIQUE DE PRESSE Eramet : Chiffre d’affaires de 775 M€ au 1er trimestre 2023 Closing de la cession d’A&D à fin avril confirmant le...
Eramet: Q1 2023 turnover of €775m
27 avr. 2023 01h30 HE
|
Eramet SA
Paris, 27 April 2023, 7:30 a.m. PRESS RELEASE Eramet: Q1 2023 turnover of €775m Closing of the sale of A&D at end-April confirming the Group's strategic repositioningAdjusted turnover1...
Euro Manganese Confirms Second Fiscal Quarter 2023 Release Date and Conference Call Details
26 avr. 2023 17h05 HE
|
Euro Manganese Inc.
VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the "Company" or "EMN") will file its Second Fiscal Quarter...
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
29 mars 2023 06h40 HE
|
Synlogic, Inc.
– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU)...
PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results
28 mars 2023 07h30 HE
|
PDS Biotechnology Corporation
Successful meeting with FDA to discuss registrational pathway for triple combination of PDS0101, PDS0301, and a commercial immune checkpoint inhibitor100% (9/9) clinical response (>60% tumor...
PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results
16 mars 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...